热增强对多形性胶质母细胞瘤化疗辐射的影响

Q4 Health Professions
S. Mahdavi, Leila Khalafi, A. Nikoofar, P. Fadavi, F. Kalateh, T. Aryafar, H. Foudazi, B. Mofid, G. Sharifi, S. Shivaliloo, H. Abdollahi
{"title":"热增强对多形性胶质母细胞瘤化疗辐射的影响","authors":"S. Mahdavi, Leila Khalafi, A. Nikoofar, P. Fadavi, F. Kalateh, T. Aryafar, H. Foudazi, B. Mofid, G. Sharifi, S. Shivaliloo, H. Abdollahi","doi":"10.18869/ACADPUB.IJRR.18.2.255","DOIUrl":null,"url":null,"abstract":"Background: Hyperthermia plays a significant role in the chemo-radiotherapy effect in different malignancies. In this research, we treated Glioblastoma multiform (GBM) patients with hyperthermia (HT) along with the chemoradiation, in order to evaluate HT efficacy in terms of tumor volume changes, survival time, and probability. Materials and Methods: Thirty-eight GBM patients were distributed into two groups identified as chemoradiation (CRT), and also CRT plus HT (CRHT). The Karnofsky Performance Status Scale (KPS) was done before, immediately and three months after treatments. Capacitive hyperthermia device was used at frequency of 13.56 MHz (Celsius 42+ GmbH, Germany) for HT one hour before the radiotherapy for 10-12 sessions. Patients in both groups underwent MR imaging (1.5 Tesla) before, 3 and 6 months after the treatments. Thermal enhancement factors (TEF) were attained in terms of clinical target volume changes, TEF(CTV), and survival probability (SP) or TEF(SP). Results: Age ranges were from 27-73 years (Mean=50) and 27-65 years (Mean=50) for CRT and CRHT groups, respectively. For 53% and 47% of cases biopsy and partial resection were accomplished in both groups, respectively. Means and standard deviations of tumor volumes were 135.42±92.5 and 58.4±104.1cm before treatment in CRT and CRHT groups, respectively, with no significant difference (P= 0.2). TEF(CTV) value was attained to be as 1.54 and 1.70 for three and six months after treatments, respectively, TEF(SP) was also equal to the 1.90. Conclusion: HT enhanced the chemoradiation effects throughout the patient survival probability and KPS. TEF may reflect the hyperthermia efficacy for a given radiation dose.","PeriodicalId":14498,"journal":{"name":"Iranian Journal of Radiation Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Thermal enhancement effect on chemo-radiation of glioblastoma multiform\",\"authors\":\"S. Mahdavi, Leila Khalafi, A. Nikoofar, P. Fadavi, F. Kalateh, T. Aryafar, H. Foudazi, B. Mofid, G. Sharifi, S. Shivaliloo, H. Abdollahi\",\"doi\":\"10.18869/ACADPUB.IJRR.18.2.255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Hyperthermia plays a significant role in the chemo-radiotherapy effect in different malignancies. In this research, we treated Glioblastoma multiform (GBM) patients with hyperthermia (HT) along with the chemoradiation, in order to evaluate HT efficacy in terms of tumor volume changes, survival time, and probability. Materials and Methods: Thirty-eight GBM patients were distributed into two groups identified as chemoradiation (CRT), and also CRT plus HT (CRHT). The Karnofsky Performance Status Scale (KPS) was done before, immediately and three months after treatments. Capacitive hyperthermia device was used at frequency of 13.56 MHz (Celsius 42+ GmbH, Germany) for HT one hour before the radiotherapy for 10-12 sessions. Patients in both groups underwent MR imaging (1.5 Tesla) before, 3 and 6 months after the treatments. Thermal enhancement factors (TEF) were attained in terms of clinical target volume changes, TEF(CTV), and survival probability (SP) or TEF(SP). Results: Age ranges were from 27-73 years (Mean=50) and 27-65 years (Mean=50) for CRT and CRHT groups, respectively. For 53% and 47% of cases biopsy and partial resection were accomplished in both groups, respectively. Means and standard deviations of tumor volumes were 135.42±92.5 and 58.4±104.1cm before treatment in CRT and CRHT groups, respectively, with no significant difference (P= 0.2). TEF(CTV) value was attained to be as 1.54 and 1.70 for three and six months after treatments, respectively, TEF(SP) was also equal to the 1.90. Conclusion: HT enhanced the chemoradiation effects throughout the patient survival probability and KPS. TEF may reflect the hyperthermia efficacy for a given radiation dose.\",\"PeriodicalId\":14498,\"journal\":{\"name\":\"Iranian Journal of Radiation Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Radiation Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18869/ACADPUB.IJRR.18.2.255\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Health Professions\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Radiation Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18869/ACADPUB.IJRR.18.2.255","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 1

摘要

背景:热疗在不同恶性肿瘤的放化疗效果中起重要作用。在本研究中,我们采用热疗(HT)联合放化疗治疗多形性胶质母细胞瘤(GBM)患者,以评估热疗在肿瘤体积变化、生存时间和概率方面的疗效。材料与方法:38例GBM患者分为放化疗组(CRT)和CRT + HT组(CRHT)。分别于治疗前、治疗即刻及治疗后3个月进行Karnofsky表现状态量表(KPS)。放疗前1小时使用电容式热疗装置,频率为13.56 MHz (Celsius 42+ GmbH, Germany),持续10-12次。两组患者在治疗前、治疗后3、6个月分别行1.5特斯拉磁共振成像。通过临床靶体积变化、TEF(CTV)、生存概率(SP)或TEF(SP)获得热增强因子(TEF)。结果:CRT组年龄27 ~ 73岁(平均50岁),CRHT组年龄27 ~ 65岁(平均50岁)。两组分别有53%和47%的病例完成了活检和部分切除。CRT组与CRHT组治疗前肿瘤体积均值为135.42±92.5 cm,标准差为58.4±104.1cm,差异无统计学意义(P= 0.2)。治疗后3个月和6个月TEF(CTV)值分别为1.54和1.70,TEF(SP)也等于1.90。结论:HT增强了放化疗的整体效果,提高了患者的生存率和KPS。TEF可以反映给定辐射剂量下的热疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Thermal enhancement effect on chemo-radiation of glioblastoma multiform
Background: Hyperthermia plays a significant role in the chemo-radiotherapy effect in different malignancies. In this research, we treated Glioblastoma multiform (GBM) patients with hyperthermia (HT) along with the chemoradiation, in order to evaluate HT efficacy in terms of tumor volume changes, survival time, and probability. Materials and Methods: Thirty-eight GBM patients were distributed into two groups identified as chemoradiation (CRT), and also CRT plus HT (CRHT). The Karnofsky Performance Status Scale (KPS) was done before, immediately and three months after treatments. Capacitive hyperthermia device was used at frequency of 13.56 MHz (Celsius 42+ GmbH, Germany) for HT one hour before the radiotherapy for 10-12 sessions. Patients in both groups underwent MR imaging (1.5 Tesla) before, 3 and 6 months after the treatments. Thermal enhancement factors (TEF) were attained in terms of clinical target volume changes, TEF(CTV), and survival probability (SP) or TEF(SP). Results: Age ranges were from 27-73 years (Mean=50) and 27-65 years (Mean=50) for CRT and CRHT groups, respectively. For 53% and 47% of cases biopsy and partial resection were accomplished in both groups, respectively. Means and standard deviations of tumor volumes were 135.42±92.5 and 58.4±104.1cm before treatment in CRT and CRHT groups, respectively, with no significant difference (P= 0.2). TEF(CTV) value was attained to be as 1.54 and 1.70 for three and six months after treatments, respectively, TEF(SP) was also equal to the 1.90. Conclusion: HT enhanced the chemoradiation effects throughout the patient survival probability and KPS. TEF may reflect the hyperthermia efficacy for a given radiation dose.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Iranian Journal of Radiation Research
Iranian Journal of Radiation Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
0.67
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Iranian Journal of Radiation Research (IJRR) publishes original scientific research and clinical investigations related to radiation oncology, radiation biology, and Medical and health physics. The clinical studies submitted for publication include experimental studies of combined modality treatment, especially chemoradiotherapy approaches, and relevant innovations in hyperthermia, brachytherapy, high LET irradiation, nuclear medicine, dosimetry, tumor imaging, radiation treatment planning, radiosensitizers, and radioprotectors. All manuscripts must pass stringent peer-review and only papers that are rated of high scientific quality are accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信